Projects

To see if your product is a good candidate for the botanical drug IND development:

Click Here

Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA)

Developed from a Chinese Traditional Medicine (CTM) herb, Dantonic® (T89) is a botanical drug consisting of extracts from 5 herbs including Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng). It also contains borneol and is in a capsule form. It is indicated for angina pectoris.

A Hemp Product-X for Treating Cancer

A hemp product, which is a mixture of cannabis and other botanical products but lacks THC, is now in the early stages of the US FDA IND process. The product is indicated for oncological purposes.

1/1

XueZhiKang (XZK) in Patients With Hyperlipidemia

Xue Zhi Kang (XZK) is a formulated traditional chinese medicine (TCM) product. It is an extract from fermented red yeast rice. It passed US FDA phase 1 and phase 2 clinical trials with demonstrated safety and lipid-lowering effects for patients with Hyperlipidemia.

1/1

A Hemp Product-Y for Pre-Diabetics and Type II Diabetics

CBD is a non-psychoactive part of the cannabis plant and is believed to have numerous medicinal benefits, including but not limited to; relieving symptoms of seizure disorders, relieving inflammation, anxiety, and nausea. Cannabidivarin (CBDV) is a homologue of CBD, a rare cannabinoid. Research revolving around CBDV is in its beginning stages but gaining momentum. While lesser known than its cousin cannabinoid, CBDV is very promising in its advantageous medicinal effects.